X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (204) 204
humans (190) 190
male (119) 119
female (113) 113
animals (101) 101
urinary bladder, overactive - drug therapy (96) 96
adrenergic beta-3 receptor agonists - therapeutic use (91) 91
overactive bladder (75) 75
mirabegron (73) 73
acetanilides - therapeutic use (70) 70
thiazoles - therapeutic use (70) 70
middle aged (65) 65
aged (60) 60
adrenergic beta-3 receptor agonists - adverse effects (59) 59
acetanilides - adverse effects (54) 54
thiazoles - adverse effects (54) 54
treatment outcome (50) 50
muscarinic antagonists - therapeutic use (47) 47
receptors, adrenergic, beta-3 - metabolism (44) 44
urology & nephrology (43) 43
adult (42) 42
adrenergic beta-3 receptor agonists - pharmacology (41) 41
rats (41) 41
urinary incontinence (41) 41
pharmacology & pharmacy (39) 39
efficacy (36) 36
double-blind (34) 34
medicine & public health (34) 34
safety (32) 32
urology (32) 32
dose-response relationship, drug (30) 30
urinary bladder - drug effects (30) 30
beta-adrenoceptor agonist (27) 27
adrenergic beta-3 receptor agonists - administration & dosage (26) 26
urinary bladder, overactive - physiopathology (26) 26
mice (25) 25
urological agents - adverse effects (24) 24
urological agents - therapeutic use (24) 24
acetanilides - administration & dosage (23) 23
adrenergic receptors (23) 23
double-blind method (23) 23
heart failure (23) 23
receptors, adrenergic, beta-3 - genetics (23) 23
thiazoles - administration & dosage (23) 23
analysis (22) 22
care and treatment (21) 21
acetanilides - pharmacology (20) 20
adrenergic beta-3 receptor agonists (20) 20
thiazoles - pharmacology (20) 20
aged, 80 and over (19) 19
antimuscarinics (19) 19
cardiac & cardiovascular systems (19) 19
cardiology (19) 19
quality of life (19) 19
urinary bladder (19) 19
adrenergic beta-agonists - pharmacology (18) 18
bladder (18) 18
young adult (18) 18
prospective studies (17) 17
tolerability (17) 17
urinary-tract symptoms (17) 17
heart (16) 16
neurosciences (16) 16
urinary bladder - physiopathology (16) 16
urination - drug effects (16) 16
acetanilides - pharmacokinetics (15) 15
adrenergic beta-antagonists - pharmacology (15) 15
article (15) 15
ethanolamines - pharmacology (15) 15
pharmacology/toxicology (15) 15
physiology (15) 15
thiazoles - pharmacokinetics (15) 15
urinary bladder, overactive - diagnosis (15) 15
beta-adrenergic receptor (14) 14
detrusor overactivity (14) 14
hypertension (14) 14
rats, sprague-dawley (14) 14
time factors (14) 14
urinary incontinence - drug therapy (14) 14
adrenergic beta-3 receptor agonists - pharmacokinetics (13) 13
beta-adrenoceptor (13) 13
drug therapy (13) 13
drug therapy, combination (13) 13
in vitro techniques (13) 13
internal medicine (13) 13
lower urinary tract symptoms (13) 13
mice, inbred c57bl (13) 13
muscarinic antagonists - adverse effects (13) 13
research (13) 13
signal transduction (13) 13
therapy (13) 13
expression (12) 12
lower urinary tract symptoms - drug therapy (12) 12
medicine, general & internal (12) 12
nitric oxide (12) 12
obstetrics & gynecology (12) 12
receptors, adrenergic, beta-3 - drug effects (12) 12
rodents (12) 12
adrenoceptor (11) 11
adrenoceptor agonist (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 3, pp. 389 - 399
Abstract Background Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3 -adrenoceptor... 
Urology | Adherence | Persistence | Antimuscarinics | Overactive bladder | Observational | Mirabegron | BETA-ADRENOCEPTOR AGONIST | MEDICATION | EFFICACY | SAFETY | TERMINOLOGY | SYMPTOMS | WOMEN | TOLERABILITY | UROLOGY & NEPHROLOGY | EXPERIENCE | URINARY-INCONTINENCE | Acetanilides - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Thiazoles - administration & dosage | Adrenergic beta-3 Receptor Agonists - adverse effects | Thiazoles - adverse effects | Young Adult | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Time Factors | Urinary Bladder, Overactive - physiopathology | Aged, 80 and over | Urological Agents - administration & dosage | Adult | Female | Retrospective Studies | Acetanilides - adverse effects | Odds Ratio | Adrenergic beta-3 Receptor Agonists - administration & dosage | Databases, Factual | Urinary Bladder, Overactive - diagnosis | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | United Kingdom | Chi-Square Distribution | Muscarinic Antagonists - administration & dosage | Medication Adherence | Aged | Longitudinal Studies | Urinary incontinence | Medicine, Experimental | Complications and side effects | Medical research | Care and treatment | Patient compliance
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Expert Opinion on Drug Discovery, ISSN 1746-0441, 04/2014, Volume 9, Issue 4, pp. 433 - 448
Journal Article
BBA - Molecular Basis of Disease, ISSN 0925-4439, 09/2018, Volume 1864, Issue 9, pp. 2972 - 2982
Transformation of white adipose tissue (WAT) to a brown adipose tissue-like (BAT-like) phenotype has emerged as an attractive approach against obesity e.g.... 
Beige/brite adipocytes | Browning | CL-326,243 | BAT | ß3 agonist | Local | Systemic | WAT | Pharmacokinetics | Dioxoles - adverse effects | Obesity - drug therapy<